1,153 filings
Page 12 of 58
8-K
AIM
AIM ImmunoTech Inc
3 Aug 20
Regulation FD Disclosure
6:30am
8-K
AIM
AIM ImmunoTech Inc
9 Jul 20
Agreement Important Precursor to Next Step, Enrollment
7:00am
8-K
AIM
AIM ImmunoTech Inc
6 Jul 20
AIM ImmunoTech Signs Material Transfer and Research Agreement with Japan’s National
9:00am
8-K
AIM
AIM ImmunoTech Inc
24 Jun 20
Entry into a Material Definitive Agreement
9:00am
424B5
AIM
AIM ImmunoTech Inc
15 Jun 20
Prospectus supplement for primary offering
5:00pm
8-K
AIM
AIM ImmunoTech Inc
15 Jun 20
AIM ImmunoTech Provides Update on Commercial Launch of Ampligen® in Argentina for the Treatment of Chronic Fatigue Syndrome
1:56pm
8-K
AIM
AIM ImmunoTech Inc
5 Jun 20
Entry into a Material Definitive Agreement
5:00pm
10-Q/A
2020 Q1
AIM
AIM ImmunoTech Inc
Quarterly report (amended)
14 May 20
8:20am
10-Q
2020 Q1
AIM
AIM ImmunoTech Inc
Quarterly report
14 May 20
12:00am
8-K
AIM
AIM ImmunoTech Inc
27 Apr 20
Entry into a Material Definitive Agreement
5:13pm
8-K
AIM
AIM ImmunoTech Inc
16 Apr 20
Results of Operations and Financial Condition
5:00pm
8-K
AIM
AIM ImmunoTech Inc
6 Apr 20
Entry into a Material Definitive Agreement
5:16pm
10-K
2019 FY
AIM
AIM ImmunoTech Inc
Annual report
30 Mar 20
5:22pm
8-K
AIM
AIM ImmunoTech Inc
26 Mar 20
Entry into a Material Definitive Agreement
8:15am
8-K
AIM
AIM ImmunoTech Inc
26 Mar 20
Departure of Directors or Certain Officers
12:00am
424B5
AIM
AIM ImmunoTech Inc
10 Mar 20
Prospectus supplement for primary offering
5:18pm
8-K
AIM
AIM ImmunoTech Inc
9 Mar 20
Regulation FD Disclosure
7:00am
424B5
AIM
AIM ImmunoTech Inc
3 Mar 20
Prospectus supplement for primary offering
4:46pm
8-K
AIM
AIM ImmunoTech Inc
18 Feb 20
Regulation FD Disclosure
6:45am
SC 13G/A
AIM
AIM ImmunoTech Inc
14 Feb 20
Beneficial ownership report (amended)
12:00am